DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
You are receiving this because you have an account on www.oneGRAVESvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
FDA Approves First Treatment for Thyroid Eye Disease (Teprotumumab)
The U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis). This approval represents the first drug approved for the treatment of thyroid eye disease.
The approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non-surgical treatment option,” said Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research.
Tepezza was approved based on the results of two studies (Study 1 and 2) consisting of a total of 170 patients with active thyroid eye disease who were randomized to either receive Tepezza or a placebo.
More from Teprotumumab News:
Teprotumumab Significantly Improves Proptosis in Thyroid eye Disease
Clinical Trial Analyses Substantiate that Teprotumumab Improves Debilitating Effects of TED
FDA Grants Priority Review of Teprotumumab Biologics License Application for the Treatment of TED
More from Teprotumumab Research:
Teprotumumab for the Treatment of Active Thyroid Eye Disease
(Authors: Raymond S. Douglas, George J. Kahaly et. al.)
Teprotumumab in the Treatment of Active TED: A Focus on Proptosis
(Author: Raymond S. Douglas)


Related Content
-
People & PlacesThe UC San Diego Thyroid Eye ClinicThe University of California (UC) San Di...
-
Evidence & EducationEnfermedad Ocular Tiroidea¿Qué es la Enfermedad Ocular Tiroidea?...
-
Evidence & EducationManagement of Graves’ Thyroidal and Extrathyroidal Disease: An UpdateContext: Invited update on the manageme...
-
Evidence & EducationThyroid-Associated Ophthalmopathy After Treatment for Graves’ Hyperthyroidism With Antithyroid Drugs or Iodine...Context: Previous randomized trials hav...
-
Videos & VisualsGraves’ Diseasehttps://medlineplus.gov/ency/images/ency...
-
People & PlacesWilliam R. Nunery, MD, FACSBorn in Lexington, Kentucky, Dr. Nunery ...
-
News & MeetingsGail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to Focus on Thyroid Eye DiseaseFor Graves’ Disease Awareness Month in...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.